StreetAlpha
ARS Pharmaceuticals, Inc. · SEC Form 4

SPRY Insider Trading

From SEC Form 435 trades in 2 yearsUpdated Nov 19, 2026

Every open market buy and sale of ARS Pharmaceuticals, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $284K sold.

← SPRY stock page

Insiders are only selling
Bought, 12 months$00 buys · 0 insiders
Sold, 12 months$284K2 sales · 2 insiders
Net−$284Kbought minus sold
Planned sales100%of sold value, 10b5-1 plans

Buying and selling by month

open market, last 12 months
DecJanFebMarAprMay2026-06: sold $284KJunJulAugSepOctNov
Bought (up)Sold (down)
AI Pro · insider alerts

Get an alert when SPRY insiders trade

We read every Form 4 the moment the SEC posts it and tell you when an SPRY officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.

Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.

Every SPRY insider trade

2 years · newest first
InsiderTypePriceHeld afterFiled
Jun 12, 2026Alexander A FitzpatrickChief Legal OfficerSale plan3,355$10.00$34K90,910Jun 12Form 4
Jun 12, 2026Eric KarasChief Commercial OfficerSale plan25,000$10.00$250K12,176Jun 12Form 4
Nov 13, 2025Brian DorseyCOOSale21,828$8.71$190K10,789Nov 14Form 4
Nov 12, 2025Justin ChakmaChief Business OfficerSale166,380$8.87$1.5M0Nov 14Form 4
Aug 21, 2025Kathleen D. ScottCFOSale plan12,500$15.00$188K10,042Aug 22Form 4
Aug 21, 2025Richard E LowenthalPresident And CEOSale plan50,000$14.49$725K1,196,494Aug 22Form 4
Aug 20, 2025Sarina TanimotoChief Medical OfficerSale plan50,000$14.08$704K1,247,447Aug 21Form 4
Jul 1, 2025Eric KarasChief Commercial OfficerSale plan15,000$16.99$255K10,315Jul 3Form 4
Jun 27, 2025James E Flynn10% ownerSale740,149$18.46$13.7M4,887,254Jul 1Form 4
Jun 18, 2025Eric KarasChief Commercial OfficerSale plan15,000$16.00$240K7,696Jun 20Form 4
May 20, 2025Kathleen D. ScottCFOSale50,000$14.10$705K7,424May 22Form 4
May 20, 2025Brent L SaundersDirectorSale120,000$14.25$1.7M0May 22Form 4
May 20, 2025Alexander A FitzpatrickChief Legal OfficerSale102,969$14.10$1.5M89,613May 22Form 4
Apr 7, 2025Laura ShawverDirectorSale plan50,002$12.30$615K210,346Apr 8Form 4
Mar 20, 2025Eric KarasChief Commercial OfficerSale plan10,000$14.00$140K7,696Mar 21Form 4
🔒 20 more trades. Create a free account or sign in to see them all.

SPRY insider trading FAQ

Are SPRY insiders buying or selling?

Insiders are only selling over the last 12 months. 0 insiders bought $0 of SPRY on the open market in 0 trades, and 2 sold $284K in 2 trades, 100% of that under pre-arranged trading plans.

When did an SPRY insider last buy shares?

There has been no open market insider purchase of SPRY in the last two years.

When did an SPRY insider last sell shares?

Alexander A Fitzpatrick (Chief Legal Officer) sold 3,355 shares for $34K on Jun 12, 2026, under a pre-arranged trading plan.

What is a Form 4?

Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.

Why do insider sales matter less than buys?

Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.

From SEC Form 4 filings · Not investment advice